SAN FRANCISCO--(BUSINESS WIRE)--BioMed Realty announced today they have been awarded a Deal of the Year Award for their Zymergen lease at Emeryville Center of Innovation, presented by the San Francisco Business Times. Additionally, BioMed Realty’s President and CEO Tim Schoen has been recognized as the Dealmaker of the Year.
Select real estate projects and deals from the Bay Area were named winners of the annual real estate deals of the year awards program presented by the San Francisco Business Times. Winners were announced in the May 15, 2020 edition of the publication. These are projects and deals that stood out for their size, significance and complexity.
“We certainly had two big years that included our East Bay expansion with the acquisition of the Emeryville Center of Innovation led by our Investments team and the significant development and leasing progress at our Gateway of Pacific campus in South San Francisco,” said Tim Schoen, President and CEO of BioMed Realty.
“BioMed showed great confidence in commercial real estate in 2019, making huge plays on both sides of the Bay. They not only signed two big biotech leases, they invested heavily in Emeryville, making a long-term investment on the emerging biotech scene in the East Bay,” said Doug Fruehling, editor in chief at the San Francisco Business Times. “They represent the best of what we look for in a ‘Dealmaker of the Year’ — a company with an eye on the future that isn’t afraid to embrace the whole region.”
BioMed Realty expanded its footprint in the Bay Area in March 2019 with the addition of the Emeryville Center of Innovation. This six-story life science and research facility, containing 300,000 square feet, is now entirely leased to Zymergen, a leading science and material innovation company and one of the largest employers in Emeryville. In addition, the campus also includes adjacent land supporting 830,000 square feet of future development in multiple phases. With the continued support from the City of Emeryville, the campus represents in excess of one million square feet for innovative biotech and laboratory users to conduct world class research.
The Gateway of Pacific is located at the front entrance to South San Francisco’s life science hub and is bigger than just the campus and buildings. It is about creating a new center of gravity that life science and technology companies can use to attract and retain top talent. The project contains best in class amenities, including a free-standing 50,000-square-foot amenities center that features a food hall, restaurant, and a health club and spa.
Upon completion, Gateway of Pacific, will be a two million square foot campus built in five phases:
- Phase I: 509,000 rentable square feet is substantially complete and 94% leased to AbbVie
- Phase II: 441,000 square feet, with 55% leased to Amgen
- Phase III: 13-story lab/office building totaling 350,000 square feet
- Phase IV & V: concept design and master planning are complete. BioMed Realty is seeking City approval for 590,000 square feet.
“These developments are years in the making and require a large and dedicated team to navigate each critical milestone,” Schoen continued. “I especially want to acknowledge the contributions of Denis Sullivan, our Chief Investment Officer and Scott Altick, our San Francisco Market Lead, for their work in acquiring, creating and leasing the Emeryville Center of Innovation; and our Development team, led by Chief Development Officer, Jon Bergschneider and Vice President, Salil Payappilly, for putting Gateway of Pacific on the map, which has already become a destination for innovative, blue chip companies in the life science and technology sectors.”
“We are honored to receive these awards and look forward to continuing to serve the life science industry and our communities for years to come,” said Schoen. “The Dealmaker of the Year award is really a culmination of many deals across our Bay Area markets and a recognition of our very talented team and fully-integrated platform serving the life science and technology industries.”
About BioMed Realty
BioMed Realty, a Blackstone portfolio company, is the leading provider of real estate solutions to the life science and technology industries. They own and operate high quality life science real estate comprising 11.2 million square feet located in the leading innovation markets throughout the United States and United Kingdom, led by Boston-Cambridge, San Francisco, San Diego, Seattle, New York and Cambridge U.K. In addition, they maintain a premier development platform with 2.4 million square feet of Class A properties in active construction to meet the growing demand of the life science industry.
About San Francisco Business Times
San Francisco Business Times is the #1 print and online source for Bay Area business news and information on the most successful people, companies and transactions in the region. Every Friday, the Business Times arrives with an in-depth lineup of breaking local news stories, business profiles and valuable industry rankings. From technology and sustainability to small business, biotech, hospitality, real estate and banking, the Business Times covers the most relevant and timely topics for the Bay Area business community.
SanFranciscoBusinessTimes.com takes the Business Times brand known for its insight, analysis and high journalistic standards and extends it to the Internet. Thousands of established and up and coming executives visit SanFranciscoBusinessTimes.com every day looking for the information they need to do Business in the Bay Area.
